Free tool
FAERS Monitor: Brethine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017849 or its brand name (Brethine, Terbutaline Sulfate). Reports on generic versions are filed under their own applications.
Reports
1,839
Serious
1,762
96% of reports
Hospitalization
878
Death reported
169
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea426
- asthma380
- wheezing258
- pneumonia209
- cough206
- drug ineffective153
- fatigue148
- loss of personal independence in daily activities142
- therapeutic product effect incomplete124
- sleep disorder due to a general medical condition120
- nasopharyngitis112
- malaise108
- dizziness104
- vomiting103
- blood pressure increased102
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 63 |
| 2005 | 57 |
| 2006 | 51 |
| 2007 | 83 |
| 2008 | 77 |
| 2009 | 81 |
| 2010 | 77 |
| 2011 | 59 |
| 2012 | 18 |
| 2013 | 31 |
| 2014 | 28 |
| 2015 | 32 |
| 2016 | 25 |
| 2017 | 49 |
| 2018 | 54 |
| 2019 | 111 |
| 2020 | 149 |
| 2021 | 183 |
| 2022 | 189 |
| 2023 | 138 |
| 2024 | 119 |
| 2025 | 87 |
| 2026 | 78 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,320 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep disorder due to a general medical conditionSignal | 120 | 81.4 | 68.4 | 9,388 |
| wheezingSignal | 258 | 50.0 | 44.6 | 12,314 |
| asthmaSignal | 380 | 38.6 | 35.3 | 13,902 |
| loss of personal independence in daily activitiesSignal | 142 | 33.9 | 28.9 | 4,499 |
| therapeutic product effect incompleteSignal | 124 | 20.0 | 16.8 | 2,219 |
| dyspnoeaSignal | 426 | 8.6 | 7.9 | 2,936 |
| coughSignal | 206 | 8.4 | 7.4 | 1,354 |
| blood pressure increasedSignal | 102 | 7.6 | 6.3 | 585 |
| pneumoniaSignal | 209 | 7.4 | 6.5 | 1,165 |
| nasopharyngitisSignal | 112 | 7.0 | 5.8 | 570 |
| malaiseSignal | 108 | 2.8 | 2.3 | 127 |
| vomitingSignal | 103 | 2.5 | 2.1 | 94 |
| dizzinessSignal | 104 | 2.4 | 2.0 | 84 |
| fatigueSignal | 148 | 2.2 | 1.9 | 96 |
| drug ineffective | 153 | 1.3 | 1.1 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.